Extended Data Fig. 10: Tumour Resident Lgr5+ stem-like cell ablation augments 5FU treatment.
(a) Timeline for 5FU and 5FU + DT treatment in tamoxifen–induced Cldn18–LATK mice. (b) Whole mount images for stomach and liver from untreated (left, n = 4 biological replicates), 5FU alone (middle, n = 9 biological replicates) and 5FU + DT treated mice (right, n = 13 biological replicates). Tumours and metastases are marked by dotted lines. (c) Percentage of mice displaying invasive tumours and distant metastases following treatment. (d) H&E (top), Ki67 (middle) and Lgr5 (bottom two) expression in untreated (left), 5FU alone (middle) and 5FU + DT treated mice (right). (e) Quantification of reduction in tumour volume following 5FU and 5FU + DT treatment. Statistical significance was determined by one way ANOVA and Tukey’s multiple comparisons test; ****adjusted P = < 0.0001 and *adjusted P = 0.0337. (f) Quantification of proliferating cells following 5FU and 5FU + DT treatment. Statistical significance was determined by one way ANOVA and Tukey’s multiple comparisons test; ****adjusted P = < 0.0001 and **adjusted P = 0.0073. Graphs are presented as mean ± s.d. Scale bars 500μm.
